Follow us...

 

Search News Archives

Monthly Newsletter

Lab Bulletin March Newsletter

 

VIEW THE LATEST ISSUE

SUBSCRIBE Here

News Channels

 

Coronavirus (COVID-19)

New Laboratory Products

Lab News

Research & Case Studies

Microscopy | Image Analysis

Separation Science

Brochures & Literature

Videos

Events | Webinars

 

 

Conferences | Events

CLSI Releases a New Clinical Chemistry Document on Liquid Chromatography-Mass Spectrometry Methods

publication date: Nov 28, 2014
 | 
author/source: Clinical and Laboratory Standards Institute

The Clinical and Laboratory Standards Institute (CLSI) has released a new document, Liquid Chromatography-Mass Spectrometry Methods; Approved Guideline (C62-A).

C62This document provides guidance to the clinical laboratorian for the reduction of interlaboratory variance and the evaluation of interferences, assay performance, and other pertinent characteristics of clinical assays. C62-A emphasizes particular areas related to assay development and presents a standardized approach for method verification that is specific to mass spectrometry (MS) technology.

This document provides guidance for the development and verification of liquid chromatography-mass spectrometry (LC-MS) methods in the clinical laboratory. 

C62-A is intended to serve not only as a companion to CLSI document Mass Spectrometry in the Clinical Laboratory: General Principles and Guidance; Approved Guideline (C50-A), which serves as excellent general guidance for MS in the clinical laboratory, but also to provide an enhanced focus on methods, best practices, and instrumentation related to LC-MS, which is emerging as the most common approach to clinical analyses. This document is also intended to be a resource for instrument manufacturers, manufacturers of LC-MS reagents, regulatory agencies, and educators, as well as individuals responsible for developing laboratory standards and policy.

“This document will be useful as a guide for best practices in LC-MS method development and will provide a template for robust verification of LC-MS methods before implementation. Hopefully, the widespread implementation of this guideline will move the field toward harmonization of clinical LC-MS assays for various analytes,” notes William Clarke, PhD, MBA, DABCC, C62-A Document Development Committee Chairholder, and Associate Professor of Pathology and Director of Clinical Toxicology and Point-of-Care Testing at Johns Hopkins University of Medicine, Baltimore, Maryland, USA.


more about CLSI




 

 

Popular this Month...

Our Top 10 most popular articles this month

 

Today's Picks...

 

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd

 

 

Media Partners